In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity
- 592 Downloads
Impairment of mitochondrial metabolism, particularly the electron transport chain (ETC), as well as increased oxidative stress might play a significant role in pathogenesis of Alzheimer’s disease (AD). Some effects of drugs used for symptomatic AD treatment may be related to their direct action on mitochondrial function. In vitro effects of pharmacologically different cognitives (galantamine, donepezil, rivastigmine, 7-MEOTA, memantine) and nootropic drugs (latrepirdine, piracetam) were investigated on selected mitochondrial parameters: activities of ETC complexes I, II + III, and IV, citrate synthase, monoamine oxidase (MAO), oxygen consumption rate, and hydrogen peroxide production of pig brain mitochondria. Complex I activity was decreased by galantamine, donepezil, and memantine; complex II + III activity was increased by galantamine. None of the tested drugs caused significant changes in the rate of mitochondrial oxygen consumption, even at high concentrations. Except galantamine, all tested drugs were selective MAO-A inhibitors. Latrepirdine, donepezil, and 7-MEOTA were found to be the most potent MAO-A inhibitors. Succinate-induced mitochondrial hydrogen peroxide production was not significantly affected by the drugs tested. The direct effect of cognitives and nootropics used in the treatment of AD on mitochondrial respiration is relatively small. The safest drugs in terms of disturbing mitochondrial function appear to be piracetam and rivastigmine. The MAO-A inhibition by cognitives and nootropics may also participate in mitochondrial neuroprotection. The results support the future research aimed at measuring the effects of currently used drugs or newly synthesized drugs on mitochondrial functioning in order to understand their mechanism of action.
KeywordsCognitives Nootropics Mitochondrial respiration Monoamine oxidase Reactive oxygen species
Supported by International Post-Doc Research Fund of Charles University, by project PRVOUK-P26/LF1/4 given by Charles University and by grants AZV 15-28967A and 15-28616A, Ministry of Health, Czech Republic. Authors are grateful to Mr. Zdeněk Hanuš for his technical assistance.
Compliance with Ethical Standards
Conflict of Interest
The authors declare that they have no conflict of interest.
- 6.Korabecny J, Musilek K, Holas O, Nepovimova E, Jun D, Zemek F, Opletalova V, Patocka J, Dohnal V, Nachon F, Hroudova J, Fisar Z, Kuca K (2010) Synthesis and in vitro evaluation of N-(Bromobut-3-en-2-yl)-7-methoxy-1,2,3,4-tetrahydroacridin-9-amine as a cholinesterase inhibitor with regard to Alzheimer’s disease treatment. Mol (Basel, Switzerland) 15(12):8804–8812. doi: 10.3390/molecules15128804 CrossRefGoogle Scholar
- 7.Korabecny J, Musilek K, Holas O, Binder J, Zemek F, Marek J, Pohanka M, Opletalova V, Dohnal V, Kuca K (2010) Synthesis and in vitro evaluation of N-alkyl-7-methoxytacrine hydrochlorides as potential cholinesterase inhibitors in Alzheimer disease. Bioorg Med Chem Lett 20(20):6093–6095. doi: 10.1016/j.bmcl.2010.08.044 CrossRefPubMedGoogle Scholar
- 8.Arias E, Gallego-Sandin S, Villarroya M, Garcia AG, Lopez MG (2005) Unequal neuroprotection afforded by the acetylcholinesterase inhibitors galantamine, donepezil, and rivastigmine in SH-SY5Y neuroblastoma cells: role of nicotinic receptors. J Pharmacol Exp Ther 315(3):1346–1353. doi: 10.1124/jpet.105.090365 CrossRefPubMedGoogle Scholar
- 11.Sabbagh MN, Shill HA (2010) Latrepirdine, a potential novel treatment for Alzheimer’s disease and Huntington’s chorea. Curr Opin Invest Drugs (London, England : 2000) 11(1):80–91Google Scholar
- 12.Weisova P, Alvarez SP, Kilbride SM, Anilkumar U, Baumann B, Jordan J, Bernas T, Huber HJ, Dussmann H, Prehn JH (2013) Latrepirdine is a potent activator of AMP-activated protein kinase and reduces neuronal excitability. Transl Psychiatry 3:e317. doi: 10.1038/tp.2013.92 CrossRefPubMedPubMedCentralGoogle Scholar
- 13.Kurz C, Ungerer I, Lipka U, Kirr S, Schutt T, Eckert A, Leuner K, Muller WE (2010) The metabolic enhancer piracetam ameliorates the impairment of mitochondrial function and neurite outgrowth induced by beta-amyloid peptide. Br J Pharmacol 160(2):246–257. doi: 10.1111/j.1476-5381.2010.00656.x CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Leuner K, Schutt T, Kurz C, Eckert SH, Schiller C, Occhipinti A, Mai S, Jendrach M, Eckert GP, Kruse SE, Palmiter RD, Brandt U, Drose S, Wittig I, Willem M, Haass C, Reichert AS, Muller WE (2012) Mitochondrion-derived reactive oxygen species lead to enhanced amyloid beta formation. Antioxid Redox Signal 16(12):1421–1433. doi: 10.1089/ars.2011.4173 CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Folbergrová J, Jesina P, Haugvicová R, Lisý V, Houstek J (2010) Sustained deficiency of mitochondrial complex I activity during long periods of survival after seizures induced in immature rats by homocysteic acid. Neurochem Int 56(3):394–403. doi: 10.1016/j.neuint.2009.11.011 CrossRefPubMedGoogle Scholar
- 35.Ross T, Szczepanek K, Bowler E, Hu Y, Larner A, Lesnefsky EJ, Chen Q (2013) Reverse electron flow-mediated ROS generation in ischemia-damaged mitochondria: role of complex I inhibition vs. depolarization of inner mitochondrial membrane. Biochim Biophys Acta 1830(10):4537–4542. doi: 10.1016/j.bbagen.2013.05.035 CrossRefPubMedPubMedCentralGoogle Scholar
- 38.Casademont J, Miro O, Rodriguez-Santiago B, Viedma P, Blesa R, Cardellach F (2003) Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer’s disease. In: J Neurol Sci, vol 206. vol 1. Netherlands, pp 23–26Google Scholar
- 41.Wang L, Esteban G, Ojima M, Bautista-Aguilera OM, Inokuchi T, Moraleda I, Iriepa I, Samadi A, Youdim MB, Romero A, Soriano E, Herrero R, Fernandez Fernandez AP, Ricardo Martinez M, Marco-Contelles J, Unzeta M (2014) Donepezil + propargylamine +8-hydroxyquinoline hybrids as new multifunctional metal-chelators, ChE and MAO inhibitors for the potential treatment of Alzheimer’s disease. Eur J Med Chem 80:543–561. doi: 10.1016/j.ejmech.2014.04.078 CrossRefPubMedGoogle Scholar